IWBI Announces First WELL Portfolio Participants
The International WELL Building Institute™ (IWBI™) announced today the first participants in WELL Portfolio™, a new streamlined pathway for WELL Certification™ for multiple new or existing buildings and tenant spaces in a single portfolio. Being released as part of the WELL v2™ pilot, the latest iteration of the WELL Building Standard™ (WELL™), it is part of a suite of enhancements to WELL that addresses growing demand across the building industry for a program that helps owners, developers and tenants streamline and scale health and wellness upgrades to their real estate assets.
The announcement quickly follows the launch of WELL v2, the second iteration of IWBI’s pioneering WELL Building Standard. The addition of an early phase review process enabling projects to seek the WELL D&O™ designation, introduced in WELL v2, allows portfolio projects to move through the certification process in a more streamlined and systematic fashion across their asset base, with a specific focus on policies, programs and procurement guidelines. The WELL Portfolio Pathway will encourage owners to treat achieving WELL as a journey and not a destination, and to make incremental improvements across their portfolios over time, tracking their progress along the way.
Tenants, developers and investors from Europe, North America, Australia and Asia have all expressed interest in pursuing the WELL Portfolio Pathway. Many have already used WELL for individual buildings and are now looking to bring the same value and evidence-based performance to their portfolios – exemplifying their commitment to improve the health and wellness of people at scale.
Following roundtables, expert-led discussions and stakeholder engagement, organizations from across the globe have committed to piloting a sample portfolio of qualifying buildings. Their hands-on participation in the development of this pathway through the pilot process assures a program that will deliver immediate and measureable benefits to both these early adopters and those who come after.
These organizations include, among others:
Brandywine Realty Trust
CBRE Global Investors and CBRE
Forest City Realty Trust
JLL Asia Pacific
The Lendlease managed Australian Prime Property Fund (APPF) Commercial
Miron Construction Co., Inc.
SL Green Realty Corp
“The excitement around the WELL Portfolio Pathway among the world’s real estate leaders speaks volumes about the need to use our buildings as part of the toolkit to improve our health and enhance our well-being,” says IWBI CEO and Chairman Rick Fedrizzi. “Organizations know that effective change is delivered at scale, and that is the driving force behind this initiative.”
Fedrizzi noted that allowing for a phased implementation of WELL features across multiple buildings in a portfolio can be more efficient and also provide additional flexibility in the ways that owners and landlords can pursue WELL Certification. To enhance efficiency and flexibility, WELL Portfolio Pathway projects will receive custom scorecards, adapted for their respective building portfolios, and will be guided to make portfolio improvements over time. Building owners will also be able to benchmark health and wellness-related building performance, both across their own portfolios and relative to peer portfolios.
Since human and environmental sustainability go hand-in-hand, the WELL Building Standard is designed to be interoperable with leading global green building standards. Developers and property managers who have already made a green building commitment, using LEED, BREAAM, Green Star or Living Building Challenge, for instance, are well-positioned to reap the vast opportunities WELL Certified™ buildings provide.
“Whether it’s building owners looking to further differentiate their spaces to make them more attractive to tenants, or a company looking to retain and attract talent, enhance employee productivity or potentially reduce health care costs, the benefits that come with healthier, more productive employees should far outweigh the one-time investment in building improvements. WELL’s proven performance has become the de facto choice for leaders around the world who want for themselves and their tenants places and spaces designed to deliver immediate and measurable health benefits for every person in the building,” said Fedrizzi.
“SL Green has had tremendous success with USGBC’s LEED Volume Program, which allowed us to streamline the certification process across 15 properties so we were able to see the advantages of WELL Portfolio,” said Laura Vulaj, SVP and Director of Sustainability for SL Green. “We are pursuing WELL at One Vanderbilt and we’ll be able to apply lessons learned to this pilot program on a portfolio-wide scale. Most importantly, we are committed to sustaining occupant health and well-being through our partnership with IWBI.”
“JLL Asia Pacific is thrilled to be involved in the WELL Portfolio Pilot, which we are using to focus on JLL’s own property footprint, and to assist our clients in their own journey towards better health and wellbeing,” said Matthew Clifford, Head of Energy and Sustainability Services, JLL Asia Pacific. “This new tool offers great potential to further unlock health and wellness opportunities in the built environment, delivering tremendous benefits to the lives of our staff, clients and the public.”
“Investa sees the health and wellbeing of our tenants as absolutely paramount to creating thriving workplaces across the country and to the success of the organisations we host every day,” said Nina James, General Manager, Corporate Sustainability at Investa. “The portfolio pathway will enable us to articulate best practice health and wellbeing outcomes using the WELL v2 scorecard. Investa is proud to be part of this pilot, working in collaboration with world leading organisations to co-create a viable WELL solution for existing buildings.”
"Our participation in the WELL Portfolio Pilot, which integrates employee health and wellness elements into building design, is a natural fit with Prologis’ innovative approach to environmental stewardship, social responsibility and governance," said Grant Stevens, Managing Director, Global Construction and Development Services, Prologis. "Buildings constructed to the highest sustainable design standards not only reduce operating costs for our customers and our company but also promote employee wellness and productivity."
“Globally, we are seeing investors apply environmental and social performance, not only to be a good corporate citizen but as an indicator of delivering long-term risk adjusted returns,” said Josh McHutchison, Managing Director of Lendlease Investment Management Australia. “Wellbeing is one of the driving factors for creating the best precincts where people want to work, and our tenants see wellness as a way to attract and retain the very best people.”
“The spaces where we live, work, play, learn and heal have a huge impact on our lives. Their design – as well as the products that go into them – play an important role in how we function every day,” said Susan Farris, Vice President of Sustainability and Corporate Communications at Shaw. “Through our commitment to Cradle to Cradle design principles for the past 20 years, that has been a keen area of focus for us. Our participation in the WELL Portfolio further exemplifies our commitment to human health and wellness through the built environment. Like so many of our clients, we recognize the opportunity to help people thrive and innovate through the safe, healthy workspaces we provide our associates,” Farris continued.
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings and communities in ways that help people thrive. The WELL v2 pilot is a recently launched version of its popular WELL Building Standard, along with the WELL Community Standard pilot, a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI convenes and mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. More information on WELL can be found here.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an